A study reports that Compound Z lowers LDL by 15% in a single small randomized controlled trial funded by the supplement maker. Which evaluation best captures how to weigh this evidence?

Assume the supplement maker's funding guarantees better trial quality and therefore greater credibility than academic-funded research.

Reject the study outright because industry funding automatically invalidates any research regardless of methods or outcomes.

Treat it as preliminary: peer review and RCT design are strengths, but the small size, single study status, and industry funding introduce bias and reduce confidence until independent replication and larger trials confirm findings.

Accept the result as conclusive because any randomized trial, regardless of size or funding, proves efficacy and should change clinical practice immediately.